Doxorubicin and Paclitaxel Versus Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial
Laura Biganzoli(Hospital of Prato), M. Piccart(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), P. Fargeot(European Organisation for Research and Treatment of Cancer), Caroline Lohrisch(BC Cancer Agency), Robert E. Coleman(University of Sheffield), Tanja Čufer(University of Ljubljana), Luc Duchateau(Ghent University), Ron Epelbaum(University of Bern), A H Calvert(Utrecht University), Chris Twelves(University of Leeds), P.F. Bruning(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Teresa Gamucci
Cited by 220
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k